/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

GENERATION BIO CO

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$5.2 0.0235(2.35%) GBIO at 04 Dec 2025 04:32 PM Biotechnology
Lowest Today 5.19
Highest Today 5.265
Today’s Open 5.19
Prev. Close 5.11
52 Week High 13.80
52 Week Low 3.00
Day’s Range: Low 5.19 High 5.265
52-Week Range: Low 3.00 High 13.80
1 day return -
1 Week return -0.38
1 month return -2.07
3 month return -10.18
6 month return +1264.11
1 year return +285.18
3 year return -0.57
5 year return -88.95
10 year return -

Institutional Holdings

T. Rowe Price Associates, Inc. 12.56

T. Rowe Price New Horizons 7.06

US Small-Cap Growth II Equity Comp 7.06

Siren, L.L.C. 4.41

Renaissance Technologies Corp 3.83

FMR Inc 3.48

Vanguard Group Inc 3.41

Vanguard Total Stock Mkt Idx Inv 2.26

T. Rowe Price Health Sciences 2.10

BlackRock Inc 1.72

T. Rowe Price New Horizons Tr-A 1.58

Goldman Sachs Group Inc 1.58

Millennium Management LLC 1.58

Yiheng Capital LLC 1.57

Morgan Stanley - Brokerage Accounts 1.36

UBS Group AG 1.31

Bank of America Corp 1.29

Militia Capital Partners, LP 0.81

Squarepoint Ops LLC 0.77

Geode Capital Management, LLC 0.74

Vanguard Institutional Extnd Mkt Idx Tr 0.73

TD Asset Management Inc 0.51

Galileo - Biotech Innovation Fund S USD 0.46

Fidelity Extended Market Index 0.38

Susquehanna International Group, LLP 0.37

Charles Schwab Investment Management Inc 0.35

Fidelity Global Micro-Cap F 0.33

State Street Corp 0.31

Citadel Advisors Llc 0.29

T. Rowe Price U.S. Equities Tr 0.26

TD Health Sciences - I 0.25

Goldman Sachs Small Cp Val Insghts Instl 0.25

Extended Equity Market Fund K 0.15

NT Ext Equity Mkt Idx Fd - NL 0.11

T. Rowe Price US Small-Cap Growth Equity 0.10

Northern Trust Extended Eq Market Idx 0.09

NT Ext Equity Mkt Idx Fd - L 0.09

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.08

NT Col R2000 Val Idx Fd -DC -L -TierFour 0.07

JHFunds2 Health Sciences NAV 0.07

Market Status

Strong Buy: 3

Buy: 1

Hold: 3

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 34.16 M

PB Ratio 0.7103

PE Ratio 0.0

Enterprise Value -27.61 M

Total Assets 231.20 M

Volume 62620

Company Financials

Annual Revenue FY23:3026000 3.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-123831000 -123.8M, FY22:-132096000 -132.1M, FY21:-114669000 -114.7M, FY20:-76500000 -76.5M, FY19:-60332000 -60.3M

Quarterly Revenue Q3/2025:1594000 1.6M, Q2/2025:765000 0.8M, Q1/2025:8723000 8.7M, Q3/2024:7554000 7.6M, Q2/2024:4091000 4.1M

Quarterly Profit Q3/2025:190000 0.2M, Q2/2025:765000 0.8M, Q1/2025:8723000 8.7M, Q3/2024:7554000 7.6M, Q2/2024:2828000 2.8M

Quarterly Net worth Q3/2025:-5520000 -5.5M, Q2/2025:-20923000 -20.9M, Q1/2025:-14802000 -14.8M, Q3/2024:-15313000 -15.3M, Q2/2024:-20432000 -20.4M

Fund house & investment objective

Company Information Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 115

Industry Biotechnology

CEO Ms. Yalonda Howze J.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow